Showing results (21-30 of 143) with videos related to

Sort By:
Pageof 15
Postgraduate Medicine|May 14, 2010
Managing type 2 diabetes: balancing HbA1c and body weightAnnie A Mavian, Stephan Miller, Robert R Henry
Current Cardiology Reports|January 15, 2013
Beneficial and detrimental effects of glycemic control on cardiovascular disease in type 2 diabetesPam R Taub, Erin Higginbotham, Robert R Henry
Molecular Biology Reports|January 7, 2021
Impaired capillary tube formation induced by elevated secretion of IL8 involves altered signaling via the CXCR1/PI3K/MMP2 pathwayYifat Amir Levy, Theodore P Ciaraldi, Robert R Henry
Frontiers in Physiology|February 11, 2020
Myokine Regulation of Insulin Secretion: Impact of Inflammation and Type 2 DiabetesAlexander J Ryan, Theodore P Ciaraldi, Robert R Henry
Diabetes Care|November 26, 2015
Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to BedsideSunder Mudaliar, David Polidori, Brian Zambrowicz, et al.
Expert Review of Endocrinology & Metabolism|February 21, 2019
Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literatureCourtney Aavang Tibble, Tricia Santos Cavaiola, Robert R Henry
Clinical Therapeutics|April 13, 2013
A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetesRobert R Henry, Douglas Logan, Thomas Alessi, et al.
Diabetes Technology & Therapeutics|August 16, 2016
Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 StudyRobert R Henry, Eric J Klein, Jenny Han, et al.
The Journal of Clinical Endocrinology and Metabolism|April 28, 2012
Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trialRobert R Henry, Sunder Mudaliar, Linda Kanitra, et al.
Diabetes Care|October 22, 2015
Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 DiabetesRobert R Henry, Payal Thakkar, Cindy Tong, et al.
Pageof 15